Tae Min Kim - Concepedia

Author

Tae Min Kim

Seoul National University Hospital ORCID

Also Known As

Bora Oh, Donghyun Kim, Hye-Kyung Park, In Ah Kim, Jeong-Ok Lee, Kim T.M., Kim, Tae Min, Kim, Tae-Min;Kim, Jeung-Tae;Kim, Jung-Soo;Kim, Soo-Young;, Michael Btker, T M Kim

749

Publications

21.1K

Citations

H-Index

205

Concepts

All Affiliations

Seoul National University Hospital Seoul National University Seoul National University Bundang Hospital Samsung Medical Center Asan Medical Center

About

Tae Min Kim is an author at Seoul National University Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	130	8.7K
2	Health Sciences	21	35	2.2K
3	Engineering	13	15	537
4	Public Health	3	3	63
5	Management	1	1	47

Tae Min Kim

315

Publications

19.9K

Citations

H-Index

Page 1

	Year	Citations
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf, Takashi Seto, Ji‐Youn Han, New England Journal of Medicine	2020	957
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Georgina V. Long, Reinhard Dummer, Omid Hamid, The Lancet Oncology OncologyPembrolizumab Versus PlaceboMelanomaClinical TrialsMetastatic Melanoma	2019	899
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial David Planchard, Benjamin Besse, Harry J.M. Groen, The Lancet Oncology Multicentre Phase 2MedicineMetronomic TherapyPathologyCancer Treatment	2016	867
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Journal of Clinical Oncology	2019	741
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Alice T. Shaw, Tae Min Kim, Lucio Crinò, The Lancet Oncology MedicineCeritinib Versus ChemotherapyPathologyBronchial NeoplasmCancer Treatment	2017	574
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Journal of Clinical Oncology	2022	484
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial David Planchard, Tae Min Kim, Julien Mazières, The Lancet Oncology OncologyNon-small-cell Lung CancerPathologyBronchial NeoplasmImmune Checkpoint Inhibitor	2016	439
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, Carlos H. Barrios, Tae Min Kim, Journal of Clinical Oncology	2014	426
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Journal of Clinical Oncology	2019	379
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Clinical Cancer Research	2016	285

Page 1